Decitabine improves patient outcomes in myelodysplastic syndromes
By H. Kantarjian, Jean-Pierre Issa, C. Rosenfeld, J. Bennett, M. Albitar, J. Dipersio, V. Klimek, J. Slack, Carlos M. de Castro, F. Ravandi and 6 more. Cancer, 2006
1,571 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/224d34bb2a0d3897e6a7deb8939803de95cf15df
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
- Peter A. Jones
- S. Baylin
- Jean-Pierre Issa
- G. Liang
- F. Lyko
- Daniel D. De Carvalho
- F. Lay
- Xiaojing Yang
Citations in the corpus
- Transient Low Doses of DNA Demethylating Agents Exert Durable Anti-tumor Effects on Hematological and Epithelial Tumor Cells (2012, background): “Decitabine (DAC) and its analog azacitidine (AZA), two major DNA demethylating agents (Jones and Taylor, 1980), have recently emerged as potent therapies for the preleukemic hematological disease myelodysplastic syndrome (MDS), and for established leukemias (Blum et al., 2007; Cashen et al., 2010; I”
- Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. (2013, result): “In a randomized study of 170 MDS patients with IPSS intermediate-1, intermediate-2, or high risk assigned to receive decitabine or supportive care alone, the overall response rate was 17% in the decitabine arm, including 9% complete responses vs 0% in the supportive care arm.(194) Patients treated w”
- Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. (2007, neutral): “Median number of courses (range) 5 (1-18) 8 (1-17) 9 (1-15)”
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine (2008, background): “After substantial refinements in their clinical dosing schedules, both azacytidine and decitabine have now shown significant clinical benefits in the treatment of myelodysplastic syndrome (MDS), a preleukemic bone marrow disorder.(3,4) As a consequence, these drugs have now received FDA approval for”
- Gene Body Methylation can alter Gene Expression and is a Therapeutic Target in Cancer (2014, background): “They have been approved by the Food and Drug Administration (FDA) in the United States for the treatment of myelodysplastic syndrome (MDS), a preleukemic disorder (Kantarjian et al., 2006;Silvermanet al., 2002).”